Title
Phase 1 Imaging Study of 89Zr-DFO-HuMab-5B1 With HuMab-5B1
Phase 1 Study of 89Zr-DFO-HuMab-5B1 (MVT-2163) With HuMab-5B1 (MVT-5873) in Patients With Pancreatic Cancer or Other CA19-9 Positive Malignancies
Phase
Phase 1Lead Sponsor
MabVax Therapeutics, Inc.Study Type
InterventionalStatus
TerminatedIndication/Condition
Pancreatic Carcinoma Tumors That Express CA19-9Study Participants
15Open label, nonrandomized, dose-escalation trial of MVT-2163 and MVT-5873 used in performing PET scans. The study is designed to determine the best time and dose of these agents that result in the best PET image of a tumor. Subjects will be seen on days 1, 2, 4, and 7 for imaging and a clinical assessment. The last study visit is on day 28.
This is an open label, nonrandomized, dose-escalation trial of a fixed dose of MVT-2163 and varying antibody masses of MVT-5873. The study is designed to identify an optimal dose (total antibody mass) and optimal timing, for tumor imaging using PET scanning. This trial will include a dose escalation and an expansion phase. During the dose escalation portion of the study, a determination of the optimal time to perform PET imaging will be made. Following the identification of the "optimal" dose and timing, an 10 additional subjects will be imaged using the best dose and timing.
In each portion of the study subjects will have a screening visit and, no more than 28 days later, those who are eligible for the study will receive MVT-2163. Each cohort will have 3-6 subjects. Subjects in cohort 1 will be administered MVT-2163 alone on day 1. Subjects in cohorts 2 and 3 will receive MVT-5873 on day 1, followed approximately 10 minutes later by MVT-2163. Subjects will return for visits to the clinic on days 2, 4, and 7 for additional imaging and safety assessments. A follow-up visit will occur on day 28.
The study will also evaluate the tissue distribution and pharmacokinetics of MVT-2163 and, based on these data, the study will estimate the radiation dosimetry of MVT-2163. Safety assessments will be performed using ECGs, vital signs measurements, assessments of performance status, and clinical laboratory measurements.
MVT-2163 is administered intravenously as a PET imaging agent
MVT-5873 is administered intravenously as a non-radioactive blocking agent prior to administration of MVT-2163
Subjects receive 3 mg of MVT-2163 without the addition of prior MVT-5873.
Subjects receive 17 mg of MVT-5873 followed by 3 mg of MVT-2163.
Inclusion Criteria: Signed, informed consent Histologically confirmed, locally-advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) or other malignancies known to express CA19-9 positive malignancies At least one lesion by CT or MRI ≥ 2 cm ECOG performance status of 0 to 2 Absolute neutrophil count ≥1.50 x 109/L Hemoglobin ≥ 9.0 g/dL (in the absence of red blood cell transfusions in the prior 14 days) Platelet count >75,000/ mm3 AST/SGOT, ALT/SGPT ≤2.5 x ULN, unless liver metastases are clearly present, then ≤5.0 x ULN Total bilirubin <1.5x the upper limit of normal unless considered due to Gilbert's syndrome in which case, <3x the upper limit of normal Serum creatinine (serum or plasma) ≤ 1.5 x ULN or GFR>50 mL/min Serum albumin > 3.0g/dL Willingness to participate in collection of pharmacokinetic samples Willingness to use adequate contraception throughout study and for a period of 90 days last dose of study drug Exclusion Criteria: Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy Major surgery other than diagnostic surgery within 28 days History of anaphylactic reaction to human, or humanized, antibody Other on-going cancer therapy or investigational agents (except MVT-5873 ) Known history of HIV or Hepatitis C Pregnant or currently breast-feeding Psychiatric illness/social situations that would interfere with compliance with study requirements Significant cardiovascular risk including, but not limited to, recent (within 28 days) coronary stenting or myocardial infarction within 6 months
